♥

Marksans Pharma Limited

ISIN : INE750C01026
NSE : MARKSANS
BSE : 524404
Face Value : 1
Industry : Pharmaceuticals & Drugs

EPS : 6.92
EPS (TTM) : 7.37
Price to Earning (P/E) : 32.15
Book Value : 45.57
Price to Bookvalue (P/B) : 4.88
Dividend Yield : 0 %
Return on Equity (ROE) : 16.53 %
Return on Capital Employed (ROCE) : 22.40 %

Marksans Pharma share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	164.15 - 168.15 2.4 %
Low / High	160.75 - 170.3 5.9 %
Trade Volume	37,055
52 Week Low / High	156 - 270.6 73.5 %

YOU MAY ALSO LIKE

Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Share Market basics for beginners
Share Market jargons in simple terms
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Stock market course tutorial
Stock Market Investment Course explained in simple words.

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR MARKSANS PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	4180.43	4337.68	4525.65	4798.29	4859.76	5000.33	5312.36	5861.27	5600.13	5906.18
Total Income	4333.87	4502.67	4667.18	4974.81	4969.85	5101.29	5502.32	5909.27	5765.42	6055.67
Total Expenditure	3544.03	3609.07	3722.98	4031.85	3764.27	3980.67	4172.87	4531.05	4503.71	4621.82
Other Income	153.44	164.99	141.53	176.52	110.09	100.96	189.96	48	165.29	149.49
Operating Profit	789.84	893.6	944.2	942.96	1205.58	1120.62	1329.45	1378.22	1261.71	1433.85
Interest	50.28	18	25.36	23.52	24.4	15.76	16.26	31.61	48.41	29.24
PBDT	739.56	875.6	918.84	919.44	1181.18	1104.86	1313.19	1346.61	1213.3	1404.61
Depreciation	213.57	111.15	140.52	127.42	139.44	136.6	175.51	220.03	210.55	204.43
Profit Before Tax	525.99	764.45	778.32	792.02	1041.74	968.26	1137.68	1126.58	1002.75	1200.18
Tax	229.46	162.61	177.11	168.96	214.64	263.88	299.18	296.93	226.32	309.51
Profit After Tax	296.53	601.84	601.21	623.06	827.1	704.38	838.5	829.65	776.43	890.67
Net Profit	296.53	601.84	601.21	623.06	827.1	704.38	838.5	829.65	776.43	890.67
Equity Capital	409.31	409.31	404.23	402.96	453.16	453.16	453.16	453.16	453.16	453.16
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	0.72	1.46	1.52	1.57	1.81	1.52	1.84	1.84	1.73	1.96
Diluted Eps After Extraordinary Items	0.69	1.46	1.52	1.56	1.97	1.52	1.84	1.84	1.73	1.96
Diluted Eps Before Extraordinary Items	0.69	1.46	1.52	1.56	1.97	1.52	1.84	1.84	1.73	1.96

STANDALONE QUARTERLY RESULT FOR MARKSANS PHARMA LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	1762.78	1591.52	1702.59	1727.48	1530.45	1820.41	2046.73	2413.64	2251.96	2545.27
Total Income	1839.26	1785.84	1912.93	1884.62	1573.48	2146.64	2206.04	2426.89	2373.9	2626.79
Total Expenditure	1494.1	1475.45	1364.88	1489.32	1303.36	1552.83	1673.74	1993.89	1912.91	2132.61
Other Income	76.48	194.32	210.34	157.14	43.03	326.23	159.31	13.25	121.94	81.52
Operating Profit	345.16	310.39	548.05	395.3	270.12	593.81	532.3	433	460.99	494.18
Interest	12.78	8.17	12.91	8.48	6.58	2.62	2.31	2.67	2.28	2.83
PBDT	332.38	302.22	535.14	386.82	263.54	591.19	529.99	430.33	458.71	491.35
Depreciation	46.08	45.18	45.3	41.79	35.09	47.24	84.98	84.34	74.72	68.36
Profit Before Tax	286.3	257.04	489.84	345.03	228.45	543.95	445.01	345.99	383.99	422.99
Tax	72.03	64.98	87.55	88.81	50.35	102.04	132.12	93.12	54.05	102.84
Profit After Tax	214.27	192.06	402.29	256.22	178.1	441.91	312.89	252.87	329.94	320.15
Net Profit	214.27	192.06	402.29	256.22	178.1	441.91	312.89	252.87	329.94	320.15
Equity Capital	409.31	409.31	404.23	402.96	453.16	453.16	453.16	453.16	453.16	453.16
Face Value (IN RS)	1	1	1	1	1	1	1	1	1	1
Calculated EPS	0.52	0.47	1	0.64	0.39	0.98	0.69	0.56	0.73	0.71
Diluted Eps After Extraordinary Items	0.52	0.47	1	0.63	0.43	0.98	0.69	0.56	0.73	0.71
Diluted Eps Before Extraordinary Items	0.52	0.47	1	0.63	0.43	0.98	0.69	0.56	0.73	0.71

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR MARKSANS PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	14908.4	18521.4	21774.1
Total Income	15326.9	19114.5	22278.3
Total Expenditure	12319.6	15128.2	17188.3
Other Income	418.53	593.13	504.22
Operating Profit	3007.33	3986.34	5089.99
Interest	84.46	91.28	112.03
PBDT	2922.87	3895.06	4977.96
Depreciation	447.76	518.53	742.7
Profit Before Tax	2475.11	3376.53	4235.26
Tax	606.97	723.32	1086.31
Profit After Tax	1868.14	2653.21	3148.95
Net Profit	1868.14	2653.21	3148.95
Equity Capital	409.31	453.16	453.16
Face Value (IN RS)	1	1	1
Reserves	11613.4	16998.5	20197.4
Calculated EPS	4.56	5.88	6.92
Diluted Eps After Extraordinary Items	4.51	6.41	6.92
Diluted Eps Before Extraordinary Items	4.51	6.41	6.92

STANDALONE ANNUAL RESULT FOR MARKSANS PHARMA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	6582.89	6552.04	8532.73
Total Income	7005.4	7156.86	9153.46
Total Expenditure	5445.74	5633.01	7133.38
Other Income	422.51	604.82	620.73
Operating Profit	1559.66	1523.85	2020.08
Interest	37.95	36.13	9.88
PBDT	1521.71	1487.72	2010.2
Depreciation	176.63	167.37	291.28
Profit Before Tax	1345.08	1320.35	1718.92
Tax	305.2	291.69	381.34
Profit After Tax	1039.88	1028.66	1337.58
Net Profit	1039.88	1028.66	1337.58
Equity Capital	409.31	453.16	453.16
Face Value (IN RS)	1	1	1
Reserves	7437.42	10650	11773.9
Calculated EPS	2.54	2.27	2.95
Diluted Eps After Extraordinary Items	2.54	2.48	2.95
Diluted Eps Before Extraordinary Items	2.54	2.48	2.95

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR MARKSANS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	1376.18 Cr	1548.88 Cr	2039.52 Cr	2289.55 Cr
Sales	1368.37 Cr	1538.17 Cr	2037 Cr	2286.34 Cr
Net Sales	1376.18 Cr	1490.84 Cr	1852.14 Cr	2177.41 Cr
Increase/Decrease in Stock	-136.28 Cr	12.9 Cr	-6.39 Cr	-73.86 Cr
Raw Material Consumed	731.33 Cr	703.92 Cr	927.75 Cr	1111.98 Cr
Opening Raw Materials	91.72 Cr	117.92 Cr	150.94 Cr	202.94 Cr
Purchases Raw Materials	445.96 Cr	573.69 Cr	664.98 Cr	727.04 Cr
Closing Raw Materials	117.92 Cr	150.94 Cr	202.94 Cr	262.29 Cr
Other Direct Purchases / Brought in cost	311.57 Cr	163.25 Cr	314.78 Cr	444.28 Cr
Power & Fuel Cost	16.42 Cr	18.59 Cr	24.5 Cr	36.94 Cr
Electricity & Power	15.95 Cr	18.24 Cr	0	36.94 Cr
Employee Cost	197.32 Cr	220.3 Cr	239.37 Cr	293.64 Cr
Salaries, Wages & Bonus	188.58 Cr	203.64 Cr	223.38 Cr	275.18 Cr
Contributions to EPF & Pension Funds	5.57 Cr	15.98 Cr	14.7 Cr	17.01 Cr
Workmen and Staff Welfare Expenses	2.09 Cr	68.2 Lk	77.3 Lk	1.35 Cr
Other Manufacturing Expenses	127.47 Cr	192.77 Cr	18.74 Cr	136.67 Cr
Repairs and Maintenance	10.5 Cr	12.73 Cr	18.74 Cr	31.18 Cr
General and Administration Expenses	50.67 Cr	47.41 Cr	52.58 Cr	59.73 Cr
Rent , Rates & Taxes	14.56 Cr	7.18 Cr	15.17 Cr	15.61 Cr
Insurance	12.43 Cr	9.96 Cr	0	0
Printing and stationery	1.15 Cr	90.5 Lk	1.34 Cr	1.74 Cr
Professional and legal fees	9.51 Cr	21.12 Cr	24.06 Cr	14.84 Cr
Traveling and conveyance	2.93 Cr	4.63 Cr	9.05 Cr	11.37 Cr
Selling and Distribution Expenses	33.54 Cr	31.9 Cr	102.53 Cr	127.31 Cr
Freight and Forwarding	1.63 Cr	1.49 Cr	102.53 Cr	91.75 Cr
Miscellaneous Expenses	16.1 Cr	4.17 Cr	153.75 Cr	26.42 Cr
Bad debts /advances written off	14.28 Cr	2.63 Cr	14.36 Cr	5.16 Cr
Loss on disposal of fixed assets(net)	70,570	0	26.4 Lk	0
Loss on foreign exchange fluctuations	96.74 Lk	0	0	0
Total Expenditure	1036.57 Cr	1231.96 Cr	1512.82 Cr	1718.83 Cr
Other Income	6.69 Cr	41.85 Cr	59.31 Cr	50.42 Cr
Interest Received	1.01 Cr	5.97 Cr	12.04 Cr	33.79 Cr
Profit on sale of Fixed Assets	3.67 Lk	0	0	9.4 Lk
Foreign Exchange Gains	0	20.58 Cr	39.78 Cr	8.24 Cr
Operating Profit	346.3 Cr	300.73 Cr	398.63 Cr	509 Cr
Interest	7.99 Cr	8.45 Cr	9.13 Cr	11.2 Cr
Bank Charges etc	4.17 Cr	2.71 Cr	3.03 Cr	0
PBDT	338.32 Cr	292.29 Cr	389.51 Cr	497.8 Cr
Depreciation	36.15 Cr	44.78 Cr	51.85 Cr	74.27 Cr
Profit Before Taxation & Exceptional Items	302.16 Cr	247.51 Cr	337.65 Cr	423.53 Cr
Profit Before Tax	302.16 Cr	247.51 Cr	337.65 Cr	423.53 Cr
Provision for Tax	63.63 Cr	60.7 Cr	72.33 Cr	108.63 Cr
Current Income Tax	66.69 Cr	57.1 Cr	71.57 Cr	113.31 Cr
Deferred Tax	-3.07 Cr	3.59 Cr	1.1 Cr	-5.1 Cr
Profit After Tax	238.54 Cr	186.81 Cr	265.32 Cr	314.9 Cr
Minority Interest	-2.6 Cr	-2.24 Cr	98.7 Lk	-1.2 Cr
Consolidated Net Profit	235.94 Cr	184.57 Cr	266.31 Cr	313.7 Cr
Profit Balance B/F	85.11 Cr	334.93 Cr	509.31 Cr	777.6 Cr
Appropriations	321.05 Cr	519.5 Cr	775.62 Cr	1091.3 Cr
Other Appropriation	-13.88 Cr	10.19 Cr	-6.99 Cr	22.37 Cr
Equity Dividend %	25	25	50	60
Earnings Per Share	5.76	4.51	5.88	6.92
Adjusted EPS	5.76	4.51	5.88	6.92

STANDALONE PROFIT / LOSS FOR MARKSANS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	599.55 Cr	658.29 Cr	695.6 Cr	855.51 Cr
Sales	591.74 Cr	647.57 Cr	693.08 Cr	852.3 Cr
Net Sales	599.55 Cr	658.29 Cr	655.2 Cr	853.27 Cr
Increase/Decrease in Stock	55.4 Lk	3.89 Cr	-10.19 Cr	-7.25 Cr
Raw Material Consumed	337.36 Cr	373.7 Cr	404.64 Cr	486.18 Cr
Opening Raw Materials	56.51 Cr	76.14 Cr	90.03 Cr	107.12 Cr
Purchases Raw Materials	310.93 Cr	341.87 Cr	355.58 Cr	459.8 Cr
Closing Raw Materials	76.15 Cr	90.03 Cr	107.12 Cr	159.77 Cr
Other Direct Purchases / Brought in cost	46.07 Cr	45.71 Cr	66.14 Cr	79.03 Cr
Power & Fuel Cost	10.9 Cr	11.49 Cr	14.24 Cr	26.04 Cr
Electricity & Power	10.52 Cr	11.27 Cr	0	26.04 Cr
Employee Cost	54.64 Cr	60.46 Cr	56.09 Cr	77.19 Cr
Salaries, Wages & Bonus	49.17 Cr	57.35 Cr	50.46 Cr	71.75 Cr
Contributions to EPF & Pension Funds	2.4 Cr	2.64 Cr	4.71 Cr	4.74 Cr
Workmen and Staff Welfare Expenses	1.98 Cr	47.3 Lk	47.7 Lk	62.1 Lk
Other Manufacturing Expenses	56.39 Cr	73.81 Cr	4.24 Cr	49.96 Cr
Processing Charges	0	0	0	20.23 Cr
Repairs and Maintenance	3.57 Cr	5.25 Cr	4.24 Cr	12.49 Cr
General and Administration Expenses	14.79 Cr	16.91 Cr	21.15 Cr	26.86 Cr
Rent , Rates & Taxes	1.62 Cr	1.31 Cr	1.76 Cr	2.18 Cr
Insurance	77.17 Lk	52.2 Lk	0	0
Printing and stationery	22.72 Lk	32.5 Lk	63.8 Lk	92.9 Lk
Professional and legal fees	1.42 Cr	1.68 Cr	2.38 Cr	3.73 Cr
Traveling and conveyance	2.16 Cr	3.35 Cr	4.76 Cr	5.79 Cr
Selling and Distribution Expenses	8.56 Cr	1.78 Cr	53.97 Cr	45.79 Cr
Freight and Forwarding	52.42 Lk	68.9 Lk	53.97 Cr	43.6 Cr
Miscellaneous Expenses	2.64 Cr	2.54 Cr	19.15 Cr	8.56 Cr
Bad debts /advances written off	80.92 Lk	1 Cr	1.38 Cr	3.11 Cr
Loss on disposal of fixed assets(net)	0	0	6.1 Lk	0
Loss on foreign exchange fluctuations	98.88 Lk	0	0	0
Total Expenditure	485.84 Cr	544.57 Cr	563.3 Cr	713.34 Cr
Other Income	31.16 Cr	42.25 Cr	60.48 Cr	62.07 Cr
Interest Received	1.15 Cr	5.93 Cr	10.29 Cr	22.5 Cr
Dividend Received	28.35 Cr	9.89 Cr	10.83 Cr	25.77 Cr
Profit on sale of Fixed Assets	3.67 Lk	0	0	3.2 Lk
Foreign Exchange Gains	0	20.54 Cr	39.13 Cr	8.25 Cr
Operating Profit	144.87 Cr	155.97 Cr	152.38 Cr	202.01 Cr
Interest	5.34 Cr	3.8 Cr	3.61 Cr	98.8 Lk
Bank Charges etc	2.49 Cr	2.05 Cr	2.35 Cr	0
PBDT	139.52 Cr	152.17 Cr	148.77 Cr	201.02 Cr
Depreciation	15.19 Cr	17.66 Cr	16.74 Cr	29.13 Cr
Profit Before Taxation & Exceptional Items	124.33 Cr	134.51 Cr	132.04 Cr	171.89 Cr
Profit Before Tax	124.33 Cr	134.51 Cr	132.04 Cr	171.89 Cr
Provision for Tax	25.95 Cr	30.52 Cr	29.17 Cr	38.13 Cr
Current Income Tax	28.19 Cr	30.01 Cr	30.35 Cr	37.01 Cr
Deferred Tax	-2.24 Cr	50.4 Lk	-17.1 Lk	67.8 Lk
Profit After Tax	98.38 Cr	103.99 Cr	102.87 Cr	133.76 Cr
Consolidated Net Profit	98.38 Cr	103.99 Cr	102.87 Cr	133.76 Cr
Profit Balance B/F	-32.69 Cr	61.4 Cr	155.21 Cr	233.61 Cr
Appropriations	65.69 Cr	165.39 Cr	258.07 Cr	367.37 Cr
Other Appropriation	4.29 Cr	10.19 Cr	18.81 Cr	22.37 Cr
Equity Dividend %	25	25	50	60
Earnings Per Share	2.4	2.54	2.27	2.95
Adjusted EPS	2.4	2.54	2.27	2.95

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR MARKSANS PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	302.16 Cr	247.51 Cr	337.65 Cr	423.53 Cr
Adjustment	75.13 Cr	35.31 Cr	74.24 Cr	55.42 Cr
Changes In working Capital	-150.03 Cr	-110.7 Cr	-111.46 Cr	-126.19 Cr
Cash Flow after changes in Working Capital	227.27 Cr	172.12 Cr	300.43 Cr	352.76 Cr
Cash Flow from Operating Activities	178.74 Cr	99.26 Cr	237.41 Cr	230.41 Cr
Cash Flow from Investing Activities	-44.9 Cr	-41.69 Cr	-259.21 Cr	-140.84 Cr
Cash Flow from Financing Activitie	-15.29 Cr	79.51 Cr	197.83 Cr	-68.73 Cr
Net Cash Inflow / Outflow	118.56 Cr	137.08 Cr	176.03 Cr	20.84 Cr
Opening Cash & Cash Equivalents	93.73 Cr	212.18 Cr	206.41 Cr	382.44 Cr
Effect of Foreign Exchange Fluctuations	0	0	20,000	0
Closing Cash & Cash Equivalent	212.29 Cr	349.26 Cr	382.44 Cr	403.28 Cr

STANDALONE CASH FLOW FOR MARKSANS PHARMA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	124.33 Cr	134.51 Cr	132.04 Cr	171.89 Cr
Adjustment	-9.08 Cr	-7.93 Cr	10.91 Cr	-16.4 Cr
Changes In working Capital	12.04 Cr	-43.77 Cr	-59.6 Cr	-82.68 Cr
Cash Flow after changes in Working Capital	127.28 Cr	82.8 Cr	83.34 Cr	72.82 Cr
Cash Flow from Operating Activities	107.07 Cr	50.97 Cr	51.72 Cr	34.05 Cr
Cash Flow from Investing Activities	8.82 Cr	-8.4 Cr	-194.62 Cr	-114.22 Cr
Cash Flow from Financing Activitie	-13.53 Cr	75.86 Cr	210.02 Cr	-26.22 Cr
Net Cash Inflow / Outflow	102.36 Cr	118.44 Cr	67.12 Cr	-106.38 Cr
Opening Cash & Cash Equivalents	3.35 Cr	105.61 Cr	81.19 Cr	148.31 Cr
Effect of Foreign Exchange Fluctuations	0	0	20,000	0
Closing Cash & Cash Equivalent	105.72 Cr	224.05 Cr	148.31 Cr	41.93 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR MARKSANS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	40.93 Cr	40.93 Cr	45.32 Cr	45.32 Cr
Equity - Authorised	55 Cr	55 Cr	55 Cr	55 Cr
Equity - Issued	40.93 Cr	40.93 Cr	45.32 Cr	45.32 Cr
Equity Paid Up	40.93 Cr	40.93 Cr	45.32 Cr	45.32 Cr
Face Value	1	1	1	1
Total Reserves	845.56 Cr	1068.24 Cr	1699.85 Cr	2019.74 Cr
Securities Premium	175.13 Cr	173.19 Cr	504.5 Cr	504.5 Cr
Capital Reserves	1.22 Lk	1.2 Lk	1.2 Lk	1.2 Lk
Profit & Loss Account Balance	334.93 Cr	509.31 Cr	777.6 Cr	1068.93 Cr
General Reserves	313.74 Cr	313.74 Cr	313.74 Cr	313.74 Cr
Reserve excluding Revaluation Reserve	845.56 Cr	1068.24 Cr	1699.85 Cr	2019.74 Cr
Shareholder's Funds	886.5 Cr	1202.27 Cr	1745.16 Cr	2065.05 Cr
Minority Interest	18.86 Cr	20.7 Cr	19.91 Cr	20.85 Cr
Deferred Tax Assets / Liabilities	7.26 Cr	13.76 Cr	15.39 Cr	10.62 Cr
Deferred Tax Assets	3.56 Cr	9.16 Cr	11.82 Cr	18.77 Cr
Deferred Tax Liability	10.83 Cr	22.93 Cr	27.21 Cr	29.39 Cr
Other Long Term Liabilities	14.33 Cr	41.43 Cr	65.69 Cr	190.02 Cr
Long Term Provisions	2.11 Cr	1.86 Cr	12.74 Cr	4.56 Cr
Total Non-Current Liabilities	23.7 Cr	57.05 Cr	93.81 Cr	205.2 Cr
Trade Payables	168.66 Cr	200.08 Cr	230.6 Cr	268.28 Cr
Sundry Creditors	168.66 Cr	200.08 Cr	230.6 Cr	268.28 Cr
Other Current Liabilities	79.12 Cr	96.8 Cr	42.2 Cr	70.62 Cr
Advances received from customers	0	1.74 Cr	90.9 Lk	2.12 Cr
Short Term Borrowings	18.74 Cr	41.29 Cr	41.59 Cr	29.09 Cr
Secured ST Loans repayable on Demands	18.74 Cr	41.29 Cr	41.59 Cr	29.09 Cr
Working Capital Loans- Sec	18.74 Cr	36.29 Cr	41.59 Cr	29.09 Cr
Short Term Provisions	31.88 Cr	18.05 Cr	50.97 Cr	21.86 Cr
Provision for Tax	30.02 Cr	17.33 Cr	49.64 Cr	19.91 Cr
Total Current Liabilities	298.4 Cr	356.22 Cr	365.36 Cr	389.85 Cr
Total Liabilities	1227.45 Cr	1636.24 Cr	2224.24 Cr	2680.95 Cr
Gross Block	607.09 Cr	726.26 Cr	828.26 Cr	1193.49 Cr
Less: Accumulated Depreciation	297.73 Cr	297.96 Cr	341.95 Cr	417.55 Cr
Net Block	309.36 Cr	428.31 Cr	486.3 Cr	775.94 Cr
Capital Work in Progress	5.6 Cr	69.5 Lk	7.25 Cr	5.38 Cr
Long Term Loans & Advances	4.16 Cr	4.16 Cr	28.4 Cr	32.94 Cr
Other Non Current Assets	0	0	0	16.8 Lk
Total Non-Current Assets	325.2 Cr	435.04 Cr	524.57 Cr	818.46 Cr
Currents Investments	0	43.5 Lk	54 Lk	26.99 Cr
Quoted	0	43.5 Lk	54 Lk	0
Inventories	404.32 Cr	424.44 Cr	484.74 Cr	617.94 Cr
Raw Materials	117.92 Cr	150.94 Cr	202.94 Cr	262.29 Cr
Work-in Progress	14.76 Cr	10.7 Cr	20.45 Cr	24.8 Cr
Finished Goods	175.96 Cr	134.36 Cr	134.71 Cr	201.82 Cr
Sundry Debtors	271.38 Cr	394.78 Cr	416.85 Cr	453.18 Cr
Debtors more than Six months	0	86.6 Lk	6.1 Cr	6.46 Cr
Debtors Others	271.38 Cr	393.91 Cr	414.01 Cr	451.98 Cr
Cash and Bank	212.29 Cr	349.26 Cr	714.96 Cr	673.58 Cr
Cash in hand	4.34 Lk	2.6 Lk	2.2 Lk	3.9 Lk
Balances at Bank	212.24 Cr	349.24 Cr	714.94 Cr	673.54 Cr
Other Current Assets	13.29 Cr	29.22 Cr	23.46 Cr	30.98 Cr
Interest accrued on Investments	0	0	2.93 Cr	5.74 Cr
Prepaid Expenses	0	0	19.8 Cr	25.13 Cr
Short Term Loans and Advances	97.73 Lk	3.06 Cr	59.12 Cr	59.82 Cr
Advances recoverable in cash or in kind	97.73 Lk	0	7.48 Cr	20.3 Cr
Advance income tax and TDS	0	3.06 Cr	26.28 Cr	4.92 Cr
Total Current Assets	902.25 Cr	1201.2 Cr	1699.67 Cr	1862.49 Cr
Net Current Assets (Including Current Investments)	603.85 Cr	844.98 Cr	1334.31 Cr	1472.64 Cr
Total Assets	1227.45 Cr	1636.24 Cr	2224.24 Cr	2680.95 Cr
Contingent Liabilities	19.78 Cr	17.02 Cr	1.45 Cr	0
Total Debt	18.74 Cr	41.29 Cr	41.59 Cr	29.09 Cr
Book Value	21.66	0	38.51	45.57
Adjusted Book Value	21.66	27.1	38.51	45.57

STANDALONE BALANCE SHEET FOR MARKSANS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	40.93 Cr	40.93 Cr	45.32 Cr	45.32 Cr
Equity - Authorised	55 Cr	55 Cr	55 Cr	55 Cr
Equity - Issued	40.93 Cr	40.93 Cr	45.32 Cr	45.32 Cr
Equity Paid Up	40.93 Cr	40.93 Cr	45.32 Cr	45.32 Cr
Face Value	1	1	1	1
Total Reserves	558.79 Cr	650.64 Cr	1066 Cr	1177.39 Cr
Securities Premium	175.13 Cr	173.19 Cr	504.5 Cr	504.5 Cr
Capital Reserves	1.22 Lk	1.2 Lk	1.2 Lk	1.2 Lk
Profit & Loss Account Balance	61.41 Cr	155.21 Cr	233.61 Cr	345 Cr
General Reserves	313.74 Cr	313.74 Cr	313.74 Cr	313.74 Cr
Reserve excluding Revaluation Reserve	558.79 Cr	650.64 Cr	1066 Cr	1177.39 Cr
Shareholder's Funds	599.72 Cr	784.67 Cr	1111.32 Cr	1222.7 Cr
Deferred Tax Assets / Liabilities	8.49 Cr	9.01 Cr	8.64 Cr	9.41 Cr
Deferred Tax Assets	86.45 Lk	90.5 Lk	1.87 Cr	2 Cr
Deferred Tax Liability	9.35 Cr	9.91 Cr	10.5 Cr	11.41 Cr
Other Long Term Liabilities	13.34 Cr	3.55 Cr	5.18 Cr	7.02 Cr
Long Term Provisions	2.11 Cr	1.86 Cr	12.66 Cr	4.47 Cr
Total Non-Current Liabilities	23.94 Cr	14.41 Cr	26.48 Cr	20.9 Cr
Trade Payables	64.15 Cr	74.45 Cr	111.58 Cr	159.72 Cr
Sundry Creditors	64.15 Cr	74.45 Cr	111.58 Cr	159.72 Cr
Other Current Liabilities	20.57 Cr	78.95 Cr	97.65 Cr	105.84 Cr
Advances received from customers	0	55.47 Cr	80.53 Cr	90.36 Cr
Short Term Borrowings	0	5 Cr	0	0
Short Term Provisions	30.4 Cr	31.99 Cr	31.68 Cr	39.16 Cr
Provision for Tax	29.44 Cr	31.26 Cr	30.35 Cr	37.21 Cr
Total Current Liabilities	115.12 Cr	190.39 Cr	240.9 Cr	304.72 Cr
Total Liabilities	738.78 Cr	989.47 Cr	1378.71 Cr	1548.32 Cr
Gross Block	277.25 Cr	301.34 Cr	318.89 Cr	472.78 Cr
Less: Accumulated Depreciation	148.16 Cr	165.83 Cr	174.95 Cr	201.2 Cr
Net Block	129.08 Cr	135.51 Cr	143.94 Cr	271.58 Cr
Capital Work in Progress	0	0	3.9 Cr	0
Non Current Investments	236.07 Cr	236.07 Cr	265.75 Cr	265.75 Cr
Long Term Investment	236.07 Cr	236.07 Cr	265.75 Cr	265.75 Cr
Unquoted	236.07 Cr	236.07 Cr	265.75 Cr	265.75 Cr
Long Term Loans & Advances	4.16 Cr	4.16 Cr	26.98 Cr	30.84 Cr
Other Non Current Assets	0	0	0	16.8 Lk
Total Non-Current Assets	369.32 Cr	375.75 Cr	440.58 Cr	568.33 Cr
Currents Investments	0	43.5 Lk	54 Lk	26.99 Cr
Quoted	0	43.5 Lk	54 Lk	0
Unquoted	236.07 Cr	236.07 Cr	265.75 Cr	265.75 Cr
Inventories	93.69 Cr	103.68 Cr	130.95 Cr	190.85 Cr
Raw Materials	76.15 Cr	90.03 Cr	107.12 Cr	159.77 Cr
Work-in Progress	11.66 Cr	8.99 Cr	19.06 Cr	23.88 Cr
Finished Goods	3.36 Cr	2.99 Cr	3.29 Cr	6.4 Cr
Sundry Debtors	146.79 Cr	246.78 Cr	305.49 Cr	370.17 Cr
Debtors more than Six months	0	86.6 Lk	85.8 Lk	5.84 Cr
Debtors Others	146.79 Cr	245.92 Cr	305.08 Cr	364.33 Cr
Cash and Bank	105.72 Cr	224.05 Cr	440.26 Cr	312.23 Cr
Cash in hand	2.66 Lk	1.2 Lk	80,000	1.3 Lk
Balances at Bank	105.69 Cr	224.04 Cr	440.25 Cr	312.22 Cr
Other Current Assets	2.07 Cr	12.58 Cr	7.17 Cr	11.74 Cr
Interest accrued on Investments	0	0	2.93 Cr	5.74 Cr
Prepaid Expenses	0	0	4.24 Cr	5.89 Cr
Short Term Loans and Advances	21.2 Cr	26.21 Cr	53.71 Cr	68 Cr
Advances recoverable in cash or in kind	97.73 Lk	2.34 Cr	3.99 Cr	1.98 Cr
Advance income tax and TDS	20.22 Cr	23.86 Cr	24.36 Cr	32.29 Cr
Total Current Assets	369.46 Cr	613.72 Cr	938.13 Cr	979.99 Cr
Net Current Assets (Including Current Investments)	254.34 Cr	423.34 Cr	697.22 Cr	675.27 Cr
Total Assets	738.78 Cr	989.47 Cr	1378.71 Cr	1548.32 Cr
Contingent Liabilities	115.1 Cr	114.36 Cr	1.45 Cr	0
Total Debt	0	5 Cr	0	0
Book Value	14.65	0	24.52	26.98
Adjusted Book Value	14.65	16.9	24.52	26.98

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR MARKSANS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	5.76	4.51	5.88	6.92
CEPS(Rs)	6.71	5.66	7	8.59
DPS(Rs)	0.25	0.25	0.5	0.6
Book NAV/Share(Rs)	21.66	27.1	38.51	45.57
Tax Rate(%)	21.06	24.52	21.42	25.65
Margin Ratios
Core EBITDA Margin(%)	24.68	16.71	16.64	20.03
EBIT Margin(%)	22.54	16.53	17	18.99
Pre Tax Margin(%)	21.96	15.98	16.56	18.5
PAT Margin (%)	17.33	12.06	13.01	13.75
Cash Profit Margin (%)	19.96	14.95	15.55	17
Performance Ratios
ROA(%)	22.4	13.04	13.66	12.93
ROE(%)	31.34	18.72	18.59	16.53
ROCE(%)	39.76	23.82	22.89	22.4
Asset Turnover(x)	1.29	1.08	1.05	0.94
Sales/Fixed Asset(x)	2.35	2.42	2.62	2.26
Working Capital/Sales(x)	2.28	1.83	1.53	1.55
Efficiency Ratios
Fixed Capital/Sales(x)	0.43	0.41	0.38	0.44
Receivable days	68.26	78.56	72.63	69.35
Inventory Days	85.69	97.65	81.36	87.89
Payable days	44.06	93.88	85.31	87.7
Valuation Parameters
PER(x)	8.67	10.1	11.99	21.89
PCE(x)	7.44	8.05	10.07	17.65
Price/Book(x)	2.31	1.68	1.83	3.33
Yield(%)	0.5	0.55	0.71	0.4
EV/Net Sales(x)	1.35	1.04	1.36	2.86
EV/Core EBITDA(x)	5.34	5.18	6.32	12.23
EV/EBIT(x)	5.97	6.08	7.27	14.32
EV/CE(x)	1.51	0.95	1.13	2.97
M Cap / Sales	1.49	1.25	1.72	3.15
Growth Ratio
Net Sales Growth(%)	21.33	8.33	24.23	17.56
Core EBITDA Growth(%)	79.82	-13.16	32.55	27.69
EBIT Growth(%)	86.93	-17.47	35.48	25.36
PAT Growth(%)	97.54	-21.68	42.02	18.68
EPS Growth(%)	101.63	-21.77	30.32	17.8
Financial Stability Ratios
Total Debt/Equity(x)	0.02	0.04	0.02	0.01
Current Ratio(x)	3.02	3.37	4.65	4.78
Quick Ratio(x)	1.67	2.18	3.33	3.19
Interest Cover(x)	38.83	30.31	37.99	38.8
Total Debt/Mcap(x)	0.01	0.02	0.01	0

FINANCIAL RATIOS (STANDALONE) FOR MARKSANS PHARMA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	2.4	2.54	2.27	2.95
CEPS(Rs)	2.77	2.97	2.64	3.59
DPS(Rs)	0.25	0.25	0.5	0.6
Book NAV/Share(Rs)	14.65	16.9	24.52	26.98
Tax Rate(%)	20.87	22.69	22.09	22.18
Margin Ratios
Core EBITDA Margin(%)	18.97	17.27	13.21	16.36
EBIT Margin(%)	21.63	21.01	19.5	20.21
Pre Tax Margin(%)	20.74	20.43	18.98	20.09
PAT Margin (%)	16.41	15.8	14.79	15.63
Cash Profit Margin (%)	18.94	18.48	17.19	19.04
Performance Ratios
ROA(%)	14.59	11.88	8.69	9.17
ROE(%)	17.8	16.11	11.41	11.46
ROCE(%)	23.46	19.91	14.27	14.81
Asset Turnover(x)	0.89	0.75	0.59	0.59
Sales/Fixed Asset(x)	2.28	2.28	2.24	2.16
Working Capital/Sales(x)	2.36	1.56	1	1.27
Efficiency Ratios
Fixed Capital/Sales(x)	0.44	0.44	0.45	0.46
Receivable days	93.95	115.25	144.9	144.14
Inventory Days	51.23	54.72	61.56	68.65
Payable days	45.72	66.99	86.07	103.38
Valuation Parameters
PER(x)	20.78	17.93	31.05	51.34
PCE(x)	18	15.33	26.71	42.16
Price/Book(x)	3.41	2.7	2.87	5.62
Yield(%)	0.5	0.55	0.71	0.4
EV/Net Sales(x)	3.23	2.5	4.2	7.68
EV/Core EBITDA(x)	13.38	10.55	18.07	32.45
EV/EBIT(x)	14.95	11.9	20.3	37.92
EV/CE(x)	2.62	1.66	2	5.36
M Cap / Sales	3.41	2.83	4.88	8.05
Growth Ratio
Net Sales Growth(%)	38.33	9.8	-0.47	30.23
Core EBITDA Growth(%)	102.15	7.66	-2.3	32.56
EBIT Growth(%)	116.06	6.65	-1.92	27.45
PAT Growth(%)	159.56	5.7	-1.08	30.03
EPS Growth(%)	159.56	5.7	-10.65	30.03
Financial Stability Ratios
Total Debt/Equity(x)	0	0.01	0	0
Current Ratio(x)	3.21	3.22	3.89	3.22
Quick Ratio(x)	2.4	2.68	3.35	2.59
Interest Cover(x)	24.26	36.44	37.54	174.98

SHARE HOLDING PATTERN FOR MARKSANS PHARMA LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	48.25	48.60	49.00	43.85	43.85	43.85	43.85	43.85	43.87	43.87
FII %	4.04	4.06	4.23	15.11	14.90	15.07	15.55	15.57	18.59	21.31
DII %	0.00	0.00	0.00	0.60	0.86	0.87	0.94	0.94	0.93	1.08
Public %	46.77	46.38	45.80	39.58	37.59	37.06	35.83	35.40	33.78	30.71

PEER COMPARISON FOR MARKSANS PHARMA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR MARKSANS PHARMA

Exchange Date	Purpose	Book Closure Dates
BSE 23-Oct-2024	Board Meeting - Quarterly Results	12-Nov-2024
BSE 31-Jul-2024	Board Meeting - Quarterly Results	13-Aug-2024
BSE 30-May-2024	Dividend - Rs.0.6000 per share(60%)Final Dividend
BSE 13-May-2024	Board Meeting - Final Dividend & Audited Results	30-May-2024
BSE 17-Jan-2024	Board Meeting - Quarterly Results	13-Feb-2024
BSE 27-Oct-2023	Board Meeting - Quarterly Results	09-Nov-2023
BSE 02-Aug-2023	Board Meeting - Quarterly Results	11-Aug-2023
BSE 07-Jun-2023	Dividend - Final Dividend
BSE 17-May-2023	Board Meeting - Final Dividend & Audited Results	30-May-2023
BSE 03-Feb-2023	Board Meeting - Quarterly Results	13-Feb-2023
BSE 11-Jan-2023	Board Meeting - Inter alia, to consider and approve allotment of fully paid-up Equity Shares having face value of Re. 1/- each against the convertible warrants on preferential basis.	20-Jan-2023
BSE 02-Nov-2022	Board Meeting - Quarterly Results	14-Nov-2022
BSE 01-Aug-2022	Board Meeting - Quarterly Results	13-Aug-2022
BSE 29-Jul-2022	Book Closure - Rs.0.2500 per share(25%)Final Dividend & A.G.M.	23-Aug-2022 29-Aug-2022
BSE 29-Jul-2022	AGM - Rs.0.2500 per share(25%)Final Dividend & A.G.M.	29-Aug-2022 29-Aug-2022
BSE 04-Jul-2022	Board Meeting - Buy Back of Shares	08-Jul-2022
BSE 10-Jun-2022	SAST - Further to our letter dated 25th April, 2022, kindly be informed that the Company has completed the process of acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai, UAE.
BSE 30-May-2022	Dividend - Rs.0.2500 per share(25%)Final Dividend
BSE 16-May-2022	Board Meeting - Audited Results & Final Dividend	30-May-2022
BSE 25-Apr-2022	SAST - Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Acquisition of Access Healthcare for Medical Products L.L.C
BSE 01-Feb-2022	Board Meeting - Quarterly Results	11-Feb-2022
BSE 27-Oct-2021	Board Meeting - Quarterly Results (Revised)	10-Nov-2021
BSE 26-Oct-2021	Board Meeting - Quarterly Results	09-Nov-2021
BSE 30-Aug-2021	Book Closure - Rs.0.2500 per share(25%)Final Dividend & A.G.M.	17-Sep-2021 23-Sep-2021
BSE 30-Aug-2021	AGM - Rs.0.2500 per share(25%)Final Dividend & A.G.M.	23-Sep-2021 23-Sep-2021

CORPORATE ANNOUNCEMENTS FOR MARKSANS PHARMA

Exchange Date	Category File	Description
BSE 28-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Credit Rating As enclosed
BSE 23-Oct-2024	Intimation FILE	Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2024 MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Unaudited Financial Results (Standalone And Consolidated) For The Quarter and half year ended September 30 2024
BSE 09-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Kindly find enclosed
BSE 27-Sep-2024	Intimation FILE	Closure of Trading Window Kindly find enclosed intimation of closure of trading window
BSE 25-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Kindly find enclosed the Voting results and scrutinizer report of e-voting held at the 32nd AGM
BSE 24-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Kindly find enclosed the proceedings of 32nd AGM of the Company held on September 24 2024
BSE 13-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Kindly find enclosed
BSE 04-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Kindly find enclosed newspaper advertisement w.r.t Notice of 32nd Annual General Meeting (AGM)
BSE 02-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Kindly find enclosed
BSE 31-Aug-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Kindly find enclosed Business Responsibility and Sustainability Report (BRSR) for FY2023-24
BSE 31-Aug-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Kindly find enclosed Annual Report for FY2023-24
BSE 31-Aug-2024	Intimation FILE	Notice Of The Thirty Second Annual General Meeting Of The Company To Be Held On Tuesday September 24 2024 At 09:30 A.M. (IST) Through Electronic Mode (Video Conference Or Other Audio-Visual Means) Kindly find enclosed
BSE 26-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Kindly find enclosed newspaper publication given with regards to the 32nd Annual General Meeting of the Company.
BSE 22-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Kindly find encloed
BSE 21-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Kindly find enclosed
BSE 20-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Kindly find enclosed
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Kindly find enclosed
BSE 14-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Kindly find enclosed
BSE 13-Aug-2024	Compliance FILE	Statement Of Deviation / Variation For Quarter Ended June 30 2024 Kindly find enclosed
BSE 13-Aug-2024	Intimation FILE	Intimation Of The Date Of The Annual General Meeting And Record Date Pursuant To The Provisions Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Kindly find enclosed
BSE 13-Aug-2024	General Announcements FILE	Re-Appointment Of Mr. Varddhman Jain As Whole-Time Director Of The Company Kindly find enclosed
BSE 13-Aug-2024	Intimation FILE	Intimation Of The Record Date For Payment Of Final Dividend Pursuant To The Provisions Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 Record date for payment of final dividend
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Kindly find enclosed
BSE 13-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Kindly find enclosed
BSE 13-Aug-2024	Outcome FILE	Financial Result For Quarter Ended June 30 2024 Kindly find enclosed
BSE 13-Aug-2024	Outcome FILE	Board Meeting Outcome for Meeting Held On August 13 2024 Kindly find enclosed the outcome of Board meeting.
BSE 02-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release The Companys UK Subsidiary has received market authorization the details of which are attached
BSE 31-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Kindly find attached newspaper publication
BSE 31-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Kindly find enclosed schedule of conference call as attached
BSE 31-Jul-2024	Intimation FILE	Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2024 MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the unaudited financial results (Standalone and Consolidated) for quarter ended June 30 2024

INSIDER TRADING FOR MARKSANS PHARMA

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 05-Jun-2024 05-Jun-2024	Buy Market	63,276 @ 0.00 (0.01 %)	Sandra Saldanha
BSE 03-Jun-2024 03-Jun-2024	Buy Market	47,000 @ 0.00 (0.01 %)	Sandra Saldanha
BSE 14-Aug-2023 18-Aug-2023	Sell Market	6,500 @ 0.00 (0.00 %)	Arvind Singh
BSE 14-Aug-2023 18-Aug-2023	Sell Market	2,000 @ 0.00 (0.00 %)	Arvind Singh
BSE 14-Aug-2023 18-Aug-2023	Buy Market	3,000 @ 0.00 (0.00 %)	Arvind Singh
BSE 14-Aug-2023 18-Aug-2023	Sell Market	3,000 @ 0.00 (0.00 %)	Arvind Singh
BSE 14-Mar-2023 14-Mar-2023	Buy Market	145,000 @ 0.00 (0.03 %)	Sandra Saldanha
BSE 17-Feb-2023 17-Feb-2023	Buy Conversion of security	1,000,000 @ 0.00 (0.22 %)	Mark Saldanha
BSE 27-Feb-2023 27-Feb-2023	Buy Market	75,000 @ 0.00 (0.00 %)	Sandra Saldanha

BULK BLOCK DEALS FOR MARKSANS PHARMA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Bulk Block details found

DIVIDEND BY MARKSANS PHARMA LIMITED

Ex Dividend Date	Dividend Type	Dividend
17-Sep-2024	DIVIDEND	0.6
07-Jun-2023	DIVIDEND	0.5
19-Aug-2022	DIVIDEND	0.25
15-Sep-2021	DIVIDEND	0.25

SPLIT / BONUS BY MARKSANS PHARMA LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Marksans Pharma Limited

Marksans Pharma share price

CONSOLIDATED QUARTERLY RESULT FOR MARKSANS PHARMA LIMITED

STANDALONE QUARTERLY RESULT FOR MARKSANS PHARMA LIMITED

CONSOLIDATED ANNUAL RESULT FOR MARKSANS PHARMA LIMITED

STANDALONE ANNUAL RESULT FOR MARKSANS PHARMA LIMITED

CONSOLIDATED PROFIT / LOSS FOR MARKSANS PHARMA LIMITED

STANDALONE PROFIT / LOSS FOR MARKSANS PHARMA LIMITED

CONSOLIDATED CASH FLOW FOR MARKSANS PHARMA LIMITED

STANDALONE CASH FLOW FOR MARKSANS PHARMA LIMITED

CONSOLIDATED BALANCE SHEET FOR MARKSANS PHARMA LIMITED

STANDALONE BALANCE SHEET FOR MARKSANS PHARMA LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR MARKSANS PHARMA LIMITED

FINANCIAL RATIOS (STANDALONE) FOR MARKSANS PHARMA LIMITED

SHARE HOLDING PATTERN FOR MARKSANS PHARMA LIMITED

PEER COMPARISON FOR MARKSANS PHARMA LIMITED

CORPORATE ACTIONS FOR MARKSANS PHARMA

CORPORATE ANNOUNCEMENTS FOR MARKSANS PHARMA

INSIDER TRADING FOR MARKSANS PHARMA

BULK BLOCK DEALS FOR MARKSANS PHARMA LIMITED

DIVIDEND BY MARKSANS PHARMA LIMITED

SPLIT / BONUS BY MARKSANS PHARMA LIMITED